▶ SERMORELIN · SUBTOPIC · DOSING LITERATURE
SERMORELIN Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of SERMORELIN. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for SERMORELIN reports the following route(s) of administration: Subcutaneous (research), Intravenous (diagnostic). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of SERMORELIN.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for SERMORELIN of approximately ~10-20 minutes. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of SERMORELIN. Refer to the original publication for full protocol detail.
- Walker RF (2006) reports the SERMORELIN protocol used in Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?, published in Clin Interv Aging. PMID 18046871. See the source for the protocol-level dose range, frequency, and duration. link
- FDA Center for Drug Evaluation and Research (1997) reports the SERMORELIN protocol used in FDA approval of sermorelin (Geref) for pediatric growth hormone deficiency, published in FDA approval letter. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ Sermorelin vs CJC-1295 · what's the difference?
Sermorelin is the unmodified native GHRH(1-29) sequence with a short half-life (~10-20 min) and rapid DPP-IV cleavage. CJC-1295 is the same parent sequence with four stabilizing amino-acid substitutions that resist DPP-IV cleavage (Mod GRF 1-29, No DAC variant). CJC-1295 with DAC adds a covalent albumin-binding linker for ~1-week half-life.
▶ What is the half-life of sermorelin?
Approximately 10-20 minutes plasma half-life. The unmodified sequence is rapidly cleaved by DPP-IV. Frequent dosing or paired administration with a ghrelin-receptor agonist is used in research to amplify the GH pulse.
▶ How does sermorelin work?
Sermorelin binds the GHRH receptor (GHRH-R) on anterior-pituitary somatotrophs and triggers cAMP-mediated release of stored growth hormone. The short half-life produces a pulse closer to the natural pulsatile rhythm than longer-acting analogs.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 2-8 °C, 24 months
Reconstituted · 2-8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Previously FDA-approved as Geref (1997) for pediatric GH deficiency. Voluntarily withdrawn from US market for commercial reasons. Research-use only as of 2026.
WADA · Prohibited at all times under WADA Section S2 (GHRH analog sub-category).
RELATED PAGES
▶ LAST UPDATED · 2026-05-25